Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPC-6535 vs Asacol for maintenance of remission in ulcerative colitis
2004-000611-25Phase 3Terminated
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jul 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tetomilast in autoimmune colitis (3 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Primary Outcome Variable. Started Jul 2004; status: terminated.
02
Drugs
tetomilast
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2004-000611-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000611-25.